GSK's Head of Vaccines to step down
GlaxoSmithKline’s head of vaccines announced his decision to retire after nearly three decades of service to the firm, including a decade as a member of the board.
FTSE 100
8,068.10
10:20 15/11/24
FTSE 350
4,456.95
10:20 15/11/24
FTSE All-Share
4,415.12
10:20 15/11/24
GSK
1,316.50p
10:20 15/11/24
Pharmaceuticals & Biotechnology
19,363.19
10:20 15/11/24
Dr Moncef Slaoui, Chairman, Vaccines agreed with the Board that he would step down from his post on 30 June 2017.
Philip Hampton, Chairman, GSK, said: "On behalf of the Board, I would like to thank Moncef for his great contribution to the company. He has been personally involved in the discovery and development of some of our most innovative vaccines and spearheaded the overhaul of GSK's pharmaceutical R&D.
“GSK has been fortunate to benefit from Moncef's considerable scientific and technical experience over many years and I'm pleased that during his remaining time, he will continue to provide this valuable expertise to the Company."
As of 11:57 BST shares in GSK were 0.81% lower at 1,404.50p.